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Abstract
The retinoblastoma tumor suppressor (Rb) is a potent and ubiquitously expressed cell cycle regulator, but patients with a
germline Rb mutation develop a very specific tumor spectrum. This surprising observation raises the possibility that
mechanisms that compensate for loss of Rb function are present or activated in many cell types. In particular, p107, a
protein related to Rb, has been shown to functionally overlap for loss of Rb in several cellular contexts. To investigate the
mechanisms underlying this functional redundancy between Rb and p107 in vivo, we used gene targeting in embryonic
stem cells to engineer point mutations in two consensus E2F binding sites in the endogenous p107 promoter. Analysis of
normal and mutant cells by gene expression and chromatin immunoprecipitation assays showed that members of the Rb
and E2F families directly bound these two sites. Furthermore, we found that these two E2F sites controlled both the
repression of p107 in quiescent cells and also its activation in cycling cells, as well as in Rb mutant cells. Cell cycle assays
further indicated that activation of p107 transcription during S phase through the two E2F binding sites was critical for
controlled cell cycle progression, uncovering a specific role for p107 to slow proliferation in mammalian cells. Direct
transcriptional repression of p107 by Rb and E2F family members provides a molecular mechanism for a critical negative
feedback loop during cell cycle progression and tumorigenesis. These experiments also suggest novel therapeutic strategies
to increase the p107 levels in tumor cells.
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Introduction
The retinoblastoma gene Rb was initially identified as a
prototypic tumor suppressor through its association with heredi-
tary retinoblastoma; mutations in Rb or in genes that play a role in
the regulation of Rb function are found in virtually all types of
human cancers. The best-described function of Rb is to act as a
transcriptional co-factor: Rb regulates the activities of numerous
transcription factors and recruits chromatin remodeling complexes
to control the expression of genes involved in the control of cell
cycle progression, differentiation, and senescence. It is generally
thought that the E2F family of transcription factors, consisting of
both activating members (E2F1, E2F2, E2F3a) and some of the
repressing members (E2F3b, E2F4, E2F5), are the most critical
downstream mediators of Rb function in the control of cell cycle
progression (reviewed in [1–3]).
Although Rb is expressed in nearly all cell types [4], patients
and mice carrying heterozygous mutations for the Rb gene are
not strongly predisposed to a broad range of tumors [5–9].
Perhaps most strikingly, conditional deletion of Rb in the mouse
retina is insufficient to induce retinoblastoma [10–13], in sharp
contrast to what is observed in human patients. After it was
found that Rb is a member of a three-gene family, along with
p107 and p130, it was quickly hypothesized that one or both of
these other Rb family members may be able to compensate for
the absence of Rb in specific cell types. Indeed, Rb/p107 and Rb/
p130 double knock-out mice develop retinoblastoma [10–14].
The ability of p107 to compensate for loss of Rb has since been
observed in numerous cell types, beyond the mouse retina
[13–19].
The observation that the presence of p107 or p130 is able to
suppress some phenotypes in the absence of Rb has raised the
question of what molecular mechanisms underlie this compensa-
tory activity. Of the three Rb family members, p107 is thought to
be mostly regulated at the transcriptional level [20–22]; p107
mRNA and protein levels are generally low in non-cycling cells,
and expression increases as cells enter late G1 and S-phase [22], at
a time when the protein is being functionally inactivated through
phosphorylation. Because loss of Rb often results in increased
levels of p107 mRNA in mammalian cells [18,23–26], an
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transcription, resulting in genetic compensation rather than
general functional redundancy. The 59 regulatory region of the
human p107 gene contains two consensus E2F consensus binding
sites (TTTSSCGC where S is G or C) [27] that are almost
completely conserved among mammals (Figure 1A). These
tandem E2F sites contribute to the appropriate cell-cycle induction
of the human p107 promoter in reporter assays [22]. In addition,
E2F transcription factors directly bind to the p107 promoter in a
cell cycle-dependent manner suggesting a model in which
activating E2Fs activate the p107 promoter in late G1 and S
while repressing E2Fs are associated with the p107 promoter in G0
and early G1 [28,29]. However, many of these reporter assays
were performed using a minimal p107 promoter transiently
expressed in tumor cells lines, and may not fully recapitulate the
regulation of the endogenous allele. In addition, chromatin
immunoprecipitation (ChIP) experiments did not identify the
exact sequences bound by E2F in the p107 promoter, did not rule
out that E2F could bind to other sequences, and did not determine
if the two consensus sites were bound differently by different E2F
family members. Moreover, from these experiments, it is still
unclear how the cell cycle-dependent regulation of p107
contributes to the cellular functions of p107. Finally, as Rb
controls the activity of multiple transcription factors, whether the
E2F binding sites or other transcription factor binding sites
[30–32] (Figure 1B) mediate the repressive effects of Rb on the
p107 promoter is still unknown.
Traditional knockout studies, which delete an entire gene and
modify multiple functional interactions in cells, may often obscure
the importance of individual regulatory loops. To investigate the
mechanisms underlying transcriptional regulation of p107 in vivo,
we used gene targeting in mouse embryonic stem cells (mESCs) to
engineer point mutations in the two E2F binding sites in the
endogenous p107 promoter. Disruption of this specific cis-acting
node in the Rb/E2F network has allowed us to show that the
tandem E2F binding sites in the p107 promoter dynamically
regulate p107 levels in wild-type and Rb-deficient cells and control
p107 function during S phase.
Results
Two consensus E2F binding sites in the mouse p107
promoter contribute to activation and repression of
transcription in reporter assays
To understand the functions of the tandem E2F consensus
binding sites in the mouse p107 promoter, we first generated a
series of four luciferase constructs in which inactivating point
mutations [33] were introduced into the two consensus E2F sites,
either individually or together, into a construct containing 900 bp
of the mouse p107 promoter (Figure 1B). These constructs were
transfected into wild-type mouse embryonic stem cells (mESCs),
which contain high levels of activating E2F transcription factors as
well as limited Rb family function, due to hyperphosphorylation of
the Rb family proteins through high activity of Cyclin/Cdk
complexes [34–36]. Because mESCs are rapidly cycling, we
reasoned they would provide a good system to investigate the role
of these consensus E2F sites in the activation of the p107 promoter.
In mESCs, the p107-1* construct, which contains a mutation in
the more distal consensus E2F binding site, expressed less than half
of the luciferase activity of the wild-type construct, whereas the
p107-2* construct, which retains the more distal site but contains a
mutant proximal site, expressed nearly 70% of the wild-type
activity (Figure 1C). Simultaneous mutation of the two sites in the
p107-1*2* construct resulted in even lower expression, suggesting
that both sites contributed to some extent to the activation of the
p107 promoter, although the distal site appeared to mediate the
majority of the activation. We also found that exogenous E2F3
efficiently enhanced the activity of the wild-type and the p107-2*
constructs and to a much lesser extent that of the p107-1* and
p107-1*2* mutant promoters (Figure 1C). These observations
further suggested that the distal E2F consensus binding site
mediated the majority of the activation of p107 by E2F but did not
exclude that some activation of p107 could be mediated through
the proximal site in this context.
We next investigated the potential role of E2F-mediated
transcriptional repression in the control of p107 transcription in
quiescent cells, where p107 levels are normally low. Because
mESCs do not stably arrest in G0, the four reporter constructs
were transfected into wild-type MEFs that were then serum-
starved for 24 hours in order to induce cell cycle exit in G0. In this
system, the p107-1* construct showed a significant trend towards
increased reporter expression, suggesting that the distal site
mediated a significant amount of repression of the p107 promoter
that could not be compensated by the presence of the proximal site
(Figure 1D). However, the significant increase in luciferase activity
found with the p107-1*2* construct over the p107-1* (Figure 1D)
construct also suggested that both sites contributed to repression of
p107 to some extent in this context.
Together, these results are indicative of a model for the mouse
p107 promoter in which the distal site is most significant for both
the activation and repression of the p107 promoter, while the
proximal site contributes to a lesser extent to both functions
(Figure 1E, right). In contrast, previous experiments using the
human promoter had generated a model in which the distal
consensus E2F binding site had a more significant role in
repression of p107 while the proximal site was more important
for activation [22,27] (Figure 1E, left). This difference between the
mouse and the human promoters could potentially result from a
single polymorphism between the mouse and human sequences in
the proximal consensus E2F binding site (Figure 1A) (see
Discussion). Nevertheless, these results with plasmid reporters also
underscore the fact that the two tandem E2F consensus sites may
perform different functions in different contexts, raising the
Author Summary
The retinoblastoma tumor suppressor Rb belongs to a
family of cell cycle inhibitors along with the related
proteins p107 and p130. Strong evidence indicates that
the three family members have both specific and
overlapping functions and expression patterns in mam-
malian cells, including in cancer cells. However, the
molecular mechanisms underlying the functional differ-
ences and similarities among Rb, p107, and p130 are still
poorly understood. One proposed mechanism of com-
pensation is a negative feedback loop involving
increased p107 transcription in Rb-deficient cells. To
dissect the mechanisms controlling p107 expression in
both wild-type and Rb-deficient cells, we have engi-
neered inactivating point mutations into the E2F binding
sites in the endogenous p107 promoter using gene
targeting in mouse embryonic stem cells. Gene expres-
sion and DNA binding assays revealed that these two
sites are essential for the control of p107 transcription in
wild-type and Rb mutant cells, and cell cycle assays
showed their importance for normal functions of p107.
These experiments identify a key node in cell cycle
regulatory networks.
Mutation of E2F Binding Sites in the p107 Promoter
PLoS Genetics | www.plosgenetics.org 2 June 2010 | Volume 6 | Issue 6 | e1001003Figure 1. Regulation of the mouse p107 promoter through E2F binding sites in reporter assays. (A) Conservation of the proximal p107
promoter across mammalian species. The two tandem consensus E2F binding sites (BS1 and BS2) are each indicated by a box. (B) Schematic
representation of wild-type (WT), p107-1*, p107-2*, and p107-1*2* luciferase vectors. Transcription factor binding sites contained in this promoter
region, as identified by sequence analysis, are indicated, as is the transcription start site (arrow). Black rectangular boxes indicate E2F consensus sites;
white boxes indicate E2F consensus sites that are mutated. The inset represents the mutations (aaa) introduced in each site. (C) Relative luciferase
activity expressed by the four constructs, co-transfected with CMV-E2F3 (+) or empty pCDNA (2), in cycling mESCs. For statistical analysis, each
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p107 gene.
E2F transcription factors control endogenous p107
expression in mESCs via tandem consensus E2F binding
sites in the proximal promoter region
To examine the role of the consensus E2F binding sites in the
regulation of the endogenous p107 promoter, we generated a series
of targeting vectors designed to knock-in the same series of
mutations as those described for the luciferase vectors into the
endogenous p107 locus (Figure 2A). These vectors were electro-
porated into mESCs in order to generate heterozygous cells.
Targeting was confirmed by both 59 and 39 Southern analysis, as
well as by sequencing of amplified genomic DNA (Figure 2B and
data not shown). Wild-type control mESCs were generated
through targeting events in which the Neomycin resistance
cassette was correctly targeted but the E2F binding sites remained
untargeted. Targeted cells were then infected with an adenovirus
expressing the Cre recombinase in order to remove the resistance
cassette, followed by a second round of targeting (Figure 2C). This
procedure generated homozygous cells of three knock-in
genotypes: p107
E2F-1*/1* cells with mutations in the distal site of
both p107 alleles, p107
E2F-2*/2* cells with mutations in the
proximal site, and p107
E2F-1*2*/1*2* cells with mutations in both
E2F sites on both alleles of p107. Targeting was verified by
Southern and sequencing analysis (Figure 2D and data not shown).
To determine the role of the consensus E2F binding sites in
controlling endogenous p107 expression, we first examined p107
mRNA levels in control and homozygous mutant mESCs. In a
pattern similar to the luciferase assays, quantitative RT-PCR (RT-
qPCR) analysis showed that p107
E2F-1*/1* cells expressed 40-50%
of the p107 mRNA expressed by wild-type cells while p107
E2F-2*/2*
cells expressed 70%; p107
E2F-1*2*/1*2* cells expressed the lowest
amounts of p107 in mESCs (Figure 2E). The relative levels of p107
mRNA in these mutant cells reflected actual p107 protein
expression (Figure 2F), providing additional evidence that p107
levels in these cells are regulated largely at the transcriptional level
and suggesting that E2F activity is involved in this transcriptional
control. Importantly, the basal p107 promoter remained active
despite the knock-in mutations, validating this knock-in approach
to investigate the functional importance of discrete elements in the
p107 promoter.
We next examined if the point mutations introduced into the
p107 promoter affected the binding of E2F transcription factors
and p107, the member of the Rb family with the highest level of
expression in cycling cells [37], to the p107 regulatory regions, an
experiment that was not possible without the knock-in mutant
cells. Using quantitative ChIP analysis, we found that both E2F3
and E2F4 bound to the wild-type p107 promoter in mESCs
(Figure 2G). The p107
E2F-1*/1* and p107
E2F-1*2*/1*2* cells
demonstrated no binding for these two E2F family members to
the p107 promoter (Figure 2G), consistent with the decreased
levels of p107 expression observed in these cells (Figure 2E–2F). In
all cases, there was significant binding of both E2Fs to the
promoter of a control gene, B-Myb (Figure 2G). Rb family
members are largely inactivated by hyperphosphorylation in
undifferentiated mESCs [36]. As expected, we did not detect
any significant binding of p107 on the p107 or B-Myb promoters in
wild-type or knock-in mutant cells under these conditions
(Figure 2G) while p107 binding could be observed in asynchro-
nously cycling mouse fibroblasts at the same promoter regions
(data not shown). These experiments show that E2F transcription
factors require the consensus E2F binding sites for binding to the
p107 promoter region. They also suggest that the distal E2F
consensus binding site is the major mediator of E2F activity
controlling p107 transcription in cycling mESCs.
p107 expression is repressed in quiescent MEFs by Rb/
E2F complexes via the tandem consensus E2F binding
sites in the proximal promoter region
To understand the function of the E2F binding sites in the
control of p107 during a more normal cell cycle and in G1 arrest,
we grew MEFs from chimeric embryos generated from homozy-
gous p107
E2F-1*/1*, p107
E2F-1*2*/1*2*, and control mESCs as
indicated in Figure 3A. Due to lower numbers of chimeric
embryos derived from the p107
E2F-1*/1* cells, experiments were
only performed in this genotype after immortalization. Primary
control and p107
E2F-1*2*/1*2* MEFs were first rendered quiescent
in low serum. We found that p107
E2F-1*2*/1*2* MEFs expressed
two times more p107 mRNA than did the wild-type cells in the
same conditions (Figure 3B). This fold increase, while somewhat
variable depending on the MEF line (see below), was always
observed and is similar to the increased levels of reporter activity
observed with the p107-1*2* luciferase construct in quiescent
MEFs (Figure 1D). A similar increase was observed with p107
protein levels in these cells (Figure 3C). These data showed that
p107 expression was repressed in G0 through the E2F binding sites
present in its proximal promoter region. Accordingly, we found a
significant decrease in E2F4 binding to the p107 promoter in
quiescent immortalized p107
E2F-1*/1* and p107
E2F-1*2*/1*2* MEFs
compared to controls (Figure 3D), underscoring the role of the
distal E2F binding site in the control of p107 repression in G0-
arrested cells. p107 levels are low in quiescent cells and we did not
observe any significant binding of p107 to the B-Myb promoter in
wild-type or p107
E2F-1*/1* and p107
E2F-1*2*/1*2* quiescent immor-
talized MEFs (Figure 3D). We found some binding of p107 to its
own promoter in wild-type cells just above the non-specific signal
found with the control antibody, and there was a trend towards
decreased binding in the knock-in mutant cells (Figure 3D), even
though p107 levels are higher in the mutant cells (Figure 3C). p130
binding to the p107 promoter was decreased in p107
E2F-1*/1* and
p107
E2F-1*2*/1*2* MEFs compared to controls; interestingly, p130
binding to the B-Myb promoter was also decreased in the mutant
cells (Figure 3D). It is possible that increased p107 levels in the
mutant quiescent cells may alter the composition of the protein
complexes between members of the Rb and E2F families. One
obvious candidate whose binding to the p107 and B-Myb
promoters could also be affected and could influence p130
binding in the mutant cells is Rb itself. Detection of murine Rb at
the promoters of E2F target genes has proven challenging,
especially in cells with low levels of Rb such as MEFs [29,38–40].
While we have not measured Rb binding to the p107 promoter in
quiescent cells, we were able to detect Rb binding to the p107 and
Mcm3 promoters in cycling immortalized MEFs. We found that
Rb binding to the p107 promoter was decreased to close to
background levels in knock-in mutant cells but not changed at the
promoter of the Mcm3 gene (Figure 3E). Because of the low
intensity and the variability of the ChIP signal for Rb, we cannot
mutant construct was compared to the wild-type one and the effect of E2F3 on each construct was analyzed. (n=3) (D) Relative luciferase activity in
quiescent MEFs. (n=15) (E) Comparison of the models for the regulation of the human and mouse p107 promoters by E2F based on reporter assays.
Gradient triangles indicate the relative importance of each consensus E2F site to either activation or repression of p107.
doi:10.1371/journal.pgen.1001003.g001
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PLoS Genetics | www.plosgenetics.org 4 June 2010 | Volume 6 | Issue 6 | e1001003Figure 2. The E2F consensus binding sites in the p107 promoter are bound by E2F family members and control p107 expression in
mESCs. (A) Schematic representation of the targeting construct (top) used to knock-in mutations into the E2F sites in the endogenous p107 allele
(bottom). Mutations in the E2F sites are indicated by asterisks. Neo
R, neomycin resistance cassette; DTA, diphtheria toxin A. The black boxes indicate
E2F consensus sites, the grey boxes indicate p107 exons. (B) Representative Southern analysis for a wild-type mESC clone (+/+) and a correctly
targeted allele (+/*). Genomic DNA was digested by NdeI (N in Figure 1A) and a 59 internal probe spanning the junction between the p107 intron and
the Neo
R cassette was used (black line in Figure 1A). (C) Schematic representation of the strategy used to generate homozygous mutant mESCs. (D)
Sequencing analysis of wild-type and homozygous mutant mESCs. The knock-in mutant sequences are marked by boxes. (E) RT-qPCR analysis of p107
expression in wild-type and homozygous mutant cycling mESCs. p107 mRNA levels were calculated relative to TATA-binding protein (TBP). (n=4) (F)
Immunoblot analysis of p107 expression in mESCs. Tubulin expression is shown as a loading control. (G) Quantitative chromatin immunoprecipitation
(ChIP) analysis of E2F3 (n=5), E2F4 (n=5), and p107 (n=2) on the p107 promoter in wild-type (W) and homozygous mutant cycling mESCs. p16
antibodies serve as a negative control (n=5). Fold enrichment was calculated over an unrelated DNA sequence (actin). The B-Myb promoter is shown
as a control. The y-axis is plotted on a log2 scale.
doi:10.1371/journal.pgen.1001003.g002
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PLoS Genetics | www.plosgenetics.org 5 June 2010 | Volume 6 | Issue 6 | e1001003Figure 3. p107 repression in quiescent MEFs is mediated by the two E2F binding sites. (A) mESCs targeted by the neomycin resistance
cassette but retaining a wild-type p107 promoter and mESCs targeted by homozygous mutations into the distal (1*/1*) or both E2F sites (1*2*/1*2*)
were injected to generate chimeric embryos. Wild-type, p107
E2F-1*/1* and p107
E2F-1*2*/1*2* MEFs derived from chimeric embryos were selected for
Neomycin resistance to generate pure populations. (B) RT-qPCR analysis of p107 expression in quiescent wild-type and p107
E2F-1*2*/1*2* MEFs. (n$9)
(C) Immunoblot analysis of p107 in the same conditions. Tubulin expression is shown as a loading control. (D) Quantitative ChIP analysis of E2F4,
p107, and p130 binding on the p107 promoter in quiescent immortalized wild-type, p107
E2F-1*/1*, and p107
E2F-1*2*/1*2* MEFs. The B-Myb promoter is
shown as a control. (n=3) (E) Quantitative ChIP analysis of Rb binding to the p107 and Mcm3 promoters in cycling immortalized wild-type and
p107
E2F-1*2*/1*2* MEFs. Mouse IgG antibodies serve as a negative control. (n$3) For (D,E), fold enrichment is calculated over actin and the y-axis is
plotted on a log2 scale.
doi:10.1371/journal.pgen.1001003.g003
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promoter. However, altogether, these observations support a
model in which Rb/E2F complexes bind to the p107 promoter
through the E2F consensus binding sites.
To determine whether the de-repression observed in the
p107
E2F-1*2*/1*2* MEFs was due to the loss of a repression complex
involving Rb family members, control and p107
E2F-1*2*/1*2*
MEFs were infected with retroviruses stably expressing shRNA
molecules directed against Rb or p130 (Figure 4A, top). As
previously shown [18,20], Rb knock-down in quiescent MEFs
resulted in an increase in p107 protein levels (Figure 4A, top). In
contrast, we did not observe an increase in p107 expression in cells
with a p130 knock-down (Figure 4A, top, and data not shown). We
could not functionally test if low levels of p107 expression altered its
own transcription, although knockdown of p107 has no effect on the
expression of an eGFP transgenic reporter for p107 in either cycling
or quiescent MEFs ([20] and unpublished observations). Based on
these observations, we sought to determine the consequences of
knocking-down Rb in wild-type and p107
E2F-1*2*/1*2* cells for p107
levels. Expression of shRNA molecules in wild-type and mutant
MEFs resulted in a significant knock-down of Rb mRNA levels
(Figure 4B, left). As expected, decreased Rb levels led to increased
p107 mRNA levels in wild-type quiescent MEFs. In contrast, low
levels of Rb did not result in a further de-repression of p107 mRNA
expression in p107
E2F-1*2*/1*2* MEFs (Figure 4B, right). Moreover,
the degree of de-repression that occurred in wild-type cells upon Rb
knockdown was similar to that seen through point mutations in the
E2F binding sites (Figure 4B, right). These experiments strongly
suggested that Rb represses p107 through the two E2F binding sites
in the p107 promoter in quiescent MEFs.
In cycling mESCs (Figure 2E–2F) and in quiescent MEFs
(Figure 3B and 3C), p107 transcript levels correlate with p107
protein levels. In contrast, although quiescent wild-type MEFs
with Rb knock-down and p107
E2F-1*2*/1*2* MEFs either with or
without Rb knock-down all have similar p107 mRNA levels
(Figure 4B), our initial immunoblot analysis suggested that p107
protein levels were higher in p107
E2F-1*2*/1*2* MEFs with Rb
knock-down compared to control wild-type cells with knock-down
or knock-in mutant cells with wild-type Rb levels (Figure 4A).
Additional experiments confirmed and quantified these observa-
tions (Figure 4C). In order to explore the potential post-
transcriptional regulation of p107 levels in the absence of Rb,
we treated wild-type MEFs in the presence and absence of Rb
knockdown with cycloheximide, an inhibitor of translation. We
found that p107 levels in the Rb knockdown cells remained more
constant in the presence of cycloheximide than in wild-type cells
treated with cycloheximide (Figure 4D). These data suggest that
loss of Rb function may control p107 levels post-transcriptionally,
at least in certain contexts. Nevertheless, these observations also
support a model in which the transcriptional control of p107
expression by Rb is largely through the two E2F binding sites in
the p107 promoter.
The increased levels of p107 protein found in quiescent
p107
E2F-1*2*/1*2* MEFs that are further increased in the presence
of Rb knockdown led us to ask what functional effect these
increased levels of p107 may have on the transcription of other
E2F target genes. We performed RT-qPCR analysis on several
E2F target genes, and found that, as expected, the expression of
some of the genes examined–B-Myb, Cyclin A, and Cyclin E–was
increased in wild-type MEFs in which Rb has been knocked down
(Figure 4E, left, shows the data for B-Myb, similar data for Cyclin A
and Cyclin E are not shown); the expression of these same genes
was not increased in p107
E2F-1*2*/1*2* MEFs in which Rb has been
knocked down (Figure 4E, left). Interestingly, Cdc6 expression was
elevated in both wild-type and p107
E2F-1*2*/1*2* MEFs upon
knock-down of Rb, although a much larger increase in Cdc6
mRNA expression is observed in p107
2/2 MEFs with additional
knockdown of Rb (Figure 4E, right). Lastly, E2F1 expression was
unchanged in wild-type and p107
E2F-1*2*/1*2* MEFs with or
without Rb expression, but was de-repressed in p107
2/2 MEFs
with Rb knockdown (Figure 4E, center). These results indicate that,
in the absence of Rb, increased levels of p107 are able to repress
the expression of some, but not all E2F target genes in quiescent
MEFs.
Activation of p107 mRNA expression during cell cycle
progression in MEFs is mediated by the tandem E2F
binding sites
We next investigated the role of the E2F binding sites in the cell-
cycle dependent activation of p107 transcription. We first found
that asynchronously cycling p107
E2F-1*2*/1*2* MEFs expressed
,10% less p107 mRNA than did the wild-type cells (Figure 5A), a
decrease which was barely observable at the protein level
(Figure 5B). We speculated that because p107
E2F-1*2*/1*2* MEFs
display a 1.5-2-fold de-repression of p107 when they are in G0/
G1, this could mask a decrease in p107 expression at other phases
of the cell cycle. To investigate this possibility, we expanded and
stained control and mutant immortalized MEFs with
Hoechst33342, a DNA intercalating agent that enabled the cells
to be FACS-sorted by DNA content (Figure 5C). We found that
wild-type G1 cells expressed 2–3 times more p107 than did cells in
G0, and this level increased up to 10-fold in S phase. On the other
hand, while both p107
E2F-1*/1* and the p107
E2F-1*2*/1*2* cells
showed some cell-cycle dependent induction of p107, this
induction was lower than the induction of p107 in wild-type cells
during S-phase (Figure 5D).
To examine the regulation of p107 transcription via the two E2F
binding sites during cell cycle re-entry from G0, we synchronized
primary wild-type and p107
E2F-1*2*/1*2* MEFs through serum
starvation, and then stimulated cell-cycle re-entry through the
addition of serum in the medium. We found that p107
E2F-1*2*/1*2*
MEFs expressed higher levels of p107 than wild-type cells initially
and that the mutant cells failed to increase p107 expression as
much as the wild-type cells during cell cycle re-entry (Figure 5E),
supporting the fact that the two E2F binding sites in the p107
promoter are critical for p107 up-regulation during S phase
progression. Despite these differences in p107 levels, MEFs of both
genotypes re-entered the cell cycle with similar kinetics, as
determined by measuring the mRNA levels of the highly cell
cycle regulated gene Cdc6 (Figure 5F) and by the two-dimensional
analysis of DNA content by PI staining and BrdU incorporation
(Figure 5G). One potential reason for the similarity of the cell cycle
profiles in control and mutant cells is that p107 protein levels
reached wild-type levels in p107
E2F-1*2*/1*2* mutant MEFs
progressing through S phase (Figure 5H) in these re-entry
experiments. These observations corroborated our findings in
cells with Rb knock-down that other mechanisms exist to increase
p107 levels in some contexts, beyond the control of p107
transcriptional control by Rb/E2F complexes. Nevertheless, these
experiments also confirmed that the transcriptional control of p107
expression in cells re-entering the cell cycle is under the control of
the two E2F binding sites in its proximal promoter region.
Lower levels of p107 specifically during S phase are
sufficient to accelerate the cellular proliferation
The lower levels of p107 RNA found in p107
E2F-1*2*/1*2* cells at
the G1/S transition and during DNA replication provided a
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(A) Top: Representative immunoblot analysis of p107, Rb, and p130 expression after knockdown of Rb (shRb)o rp130 (shp130-1 and shp130-2)a s
compared to empty vector in primary quiescent MEFs. Bottom: same experiment in p107
E2F-1*2*/1*2* mutant MEFs. The asterisk shows a non-specific
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progression. As discussed above, we found that the kinetics of Cdc6
induction were largely similar between primary wild-type and
p107
E2F-1*2*/1*2* mutant MEFs, with only a slight increase in Cdc6
maximal levels and a slight acceleration of Cdc6 induction in the
mutant cells (Figure 5F). Interestingly, however, when we repeated
the same experiment with MEFs immortalized through knock-
down of p19
ARF, we found that p107
E2F-1*2*/1*2* mutant MEFs
induced Cdc6 mRNA levels more rapidly (Figure 6A), suggesting
that these mutant MEFs re-entered the cell cycle more quickly.
BrdU/PI analysis further suggested that immortalized
p107
E2F-1*2*/1*2* mutant MEFs generally entered S phase earlier
than control MEFs in this context (Figure 6B). Together, these
results suggest that p107 plays a critical role in controlling the
kinetics of entry into S-phase in immortalized cells.
These defects in cell cycle re-entry led us to investigate if altered
p107 levels may change the length of the cell cycle in
asynchronously proliferating primary cells. To investigate the
importance of the regulation of p107 transcription for cell cycle
control, we performed cell proliferation assays comparing wild-
type, p107
E2F-1*2*/1*2*, and p107
2/2 MEFs. BrdU/PI analysis of
these asynchronously growing MEFs did not reveal any significant
differences in the cell cycle profiles between the wild-type and
p107
E2F-1*2*/1*2* MEFs, although slightly more knock-in mutant
cells were in G0/G1 and slightly fewer in G2/M than wild-type
cells within this analysis; significantly more p107
2/2 MEFs were in
S-phase than in either of the other genotypes (Figure 6C). Despite
this absence of difference in BrdU incorporation, we found that
p107
E2F-1*2*/1*2* MEFs proliferated similarly to p107
2/2 MEFs
and more rapidly than wild-type cells (Figure 6D). Thus, decreased
levels of p107 mRNA specifically during S phase and in
asynchronously cycling cells, even in primary MEFs, are sufficient
to recapitulate the phenotype of p107
2/2 MEFs. Together, these
observations indicate that p107 plays an important role at specific
points during S phase in mammalian cells.
Discussion
The classical view of the E2F family of transcription factors is
that they are necessary to drive cell-cycle progression by binding to
the promoters of and activating genes necessary for S phase,
including those needed for nucleotide synthesis and DNA
replication (reviewed in [3,41]). However, it has also long been
observed that the list of E2F target genes also includes negative
regulators of the cell cycle, including p16, Rb, and p107.
Traditional knock-out studies obscure the careful balance of these
positive and negative feedback loops and the relative importance
of each individual target. The knock-in of potential binding sites
for specific transcription factors has not been extensively used
[42,43] but proves here to be an extremely informative approach
to dissect the functional role of specific nodes in complex
regulatory networks. Our experiments demonstrate that E2F
family members and Rb control p107 transcription largely through
two tandem E2F binding sites in the proximal promoter of the
p107 gene. Our data also identify functional differences between
the two sites and the E2F activity bound to these sites in different
contexts (see model in Figure 6E).
E2F transcription factors make up a diverse family whose
members can all recognize the same consensus sequence. While
some E2F transcription factors activate target gene expression,
others repress transcription, either dependent upon or indepen-
dent from their association with Rb family members. Many E2F
target genes, like p107, reveal an even more complex promoter
structure that includes two, or sometimes more, E2F consensus
sites, and each site could have distinct functions in the control of
the target gene [44–46]. Why certain promoters have several E2F
binding sites and what dictates if a site serves to repress or activate
transcription is not understood. In the specific example of p107,
our data show that the distal E2F binding site is favored by both
E2F3 and E2F4 in mESCs, indicating that activating and
repressor E2Fs may act through the same binding site in vivo.
Our data also indicate that binding to the consensus site is context-
dependent: while E2F4 binding in mESCs requires the presence of
at least one of the two binding sites, an E2F4 binding activity is still
retained in MEFs with mutations in both E2F binding sites. This
observation suggests the existence of secondary E2F binding sites
and/or the presence of co-factors, including Rb family members,
which may help tether E2Fs to a promoter region (Figure 6E). This
residual binding activity may explain why p107 levels are still
increasing during cell cycle re-entry in p107
E2F-1*2*/1*2* mutant
MEFs. In the future, the availability of cells with knock-in
mutations in individual binding sites in the p107 promoter will
provide novel tools to dissect how transcription factors and
chromatin-remodeling enzymes interact with Rb/E2F complexes
to regulate the expression of E2F target genes in different cellular
contexts.
Similar to the residual binding of the E2F transcription factors
to the mutant p107 promoter, we observed above background
levels of Rb, p130, and p107 bound to the p107 promoter in
p107
E2F-1*2*/1*2* mutant MEFs. Rb family members have been
well described to bind to many other protein binding partners,
including ATF-1 [31] and Sp1 [30]. The mouse p107 promoter
contains consensus sequences for both ATF and Sp1 (Figure 1B),
and we cannot exclude that these sites, or others, may mediate
E2F-independent binding of all three Rb-family members to
the p107 promoter. Interestingly, we also found that the
p107
E2F-1*2*/1*2* mutant MEFs demonstrated reduced binding of
p130 to the B-Myb promoter during quiescence. Expression
analysis of B-Myb did not reveal substantial de-repression in these
mutant MEFs, and increased levels of p107 were able to repress B-
Myb expression in the absence of Rb. Together these results are
consistent with the model that all three Rb family members are
able to regulate B-Myb, and that these complexes may shift in
response to altered Rb family levels. Furthermore, the trend
towards increased Rb binding to the Mcm3 promoter in the
p107
E2F-1*2*/1*2* mutant MEFs (Figure 3E) was observed at other
band that serves as a loading control; loading was also verified by Ponceau staining (not shown). (B) RT-qPCR analysis of Rb (left panel) and p107
(right panel) mRNA relative to TBP in quiescent wild-type and p107
E2F-1*2*/1*2* MEFs infected with empty vector (2) or a vector to knock-down Rb
(shRb). (n$3) (C) Immunoblot analysis (left panel) of p107 levels in cells of the indicated genotypes infected with empty vector (2) or a vector to
knock-down Rb (+). The E2F target PCNA serves as a positive control and b-Actin as a loading control. Protein quantification (right panel) is shown
relative to b-Actin levels. p107 levels were not measured in p107 mutant cells (na). (n=2) (D) Immunoblot analysis (left panel) of p107 levels in
quiescent wild-type MEFs infected with empty vector (2) or a vector to knock-down Rb (shRb) and treated with cycloheximide (CHX) for 9 and
12 hours (hrs). Quantification (right panel) is shown relative to Tubulin levels. (n=2) (E) RT-qPCR analysis of B-Myb (left panel), E2F1 (center panel), and
Cdc6 (right panel) mRNA levels relative to TBP in quiescent primary wild-type, p107
E2F-1*2*/1*2*, and p107
2/2 MEFs after knockdown of Rb as in B. For
statistical analysis, each MEF genotype was compared to the wild-type one by an unpaired Student’s t-test, and the effect of Rb knockdown on each
genotype was analyzed by a paired Student’s t-test. (n$3)
doi:10.1371/journal.pgen.1001003.g004
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PLoS Genetics | www.plosgenetics.org 9 June 2010 | Volume 6 | Issue 6 | e1001003Figure 5. E2F binding sites mediate activation of the p107 promoter in cycling cells. (A) RT-qPCR analysis of p107 mRNA relative to TBP in
asynchronously cycling primary wild-type and p107
E2F-1*2*/1*2* MEFs. (n=12) (B) Immunoblot analysis (left panel) of p107 expression in wild-type and
p107
E2F-1*2*/1*2* MEFs as in A. Tubulin expression is shown as a loading control. p107 protein quantification (right panel) is shown relative to Tubulin
levels. (n=3) (C) Representative example of Hoescht33342 staining of asynchronously cycling MEFs showing G1 and S phase populations; wild-type
and mutant cells have similar profiles (data not shown). (D) RT-qPCR analysis of immortalized WT, p107
E2F-1*/1* and p107
E2F-1*2*/1*2* MEFs. For each
genotype, G0 samples were collected after at least three days of serum starvation. Asynchronous cells were stained with Hoechst33342 and sorted by
their DNA content into G1 and S-phase samples. (n$2) (E) and (F) RT-qPCR analysis of primary wild-type and p107
E2F-1*2*/1*2* MEFs that have been
synchronized in G0 by serum starvation. DMEM supplemented with 20% serum was added at time 0, and extracts were collected at 10 hrs, 16 hrs,
22 hrs, and 28 hrs post-stimulation. (E) p107 mRNA and (F) Cdc6 mRNA. n$8 for both genotypes at all time points. (G) Percentage of cells in S-phase
in primary MEFs collected during cell-cycle re-entry as in E. and F. Percentages were calculated by BrdU/PI analysis (n=3). (H) Immunoblot analysis of
p107 protein expression in primary wild-type and p107
E2F-1*2*/1*2* MEF extracts collected at 0 hr, 8 hrs, 12 hrs, 16 hrs, 20 hrs, and 24 hrs post-
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further suggest that p130 is displaced by Rb in these cells.
The tandem E2F consensus sites in the human p107 promoter
had previously been demonstrated to have differential functions
over control of p107 [27]. In contrast, our experiments show that
the distal site is most important for both activation and repression
of the p107 promoter in mouse cells. This discrepancy could be
explained by the presence of a single point mutation in the mouse
promoter, which makes the proximal site a less perfect E2F
consensus site. We found that correcting the proximal site in the
mouse p107 promoter (TTTGTCGC R TTTGGCGC) did
increase the activity of this promoter in luciferase assays
approximately 3 fold relatively to the parental construct
(unpublished data). However, in the absence of an intact distal
site, the activity of even the ‘‘corrected’’ construct was substantially
lower than that of a wild-type construct, further emphasizing the
relative importance of this site in the mouse p107 promoter. These
results also suggest that the human promoter, with two perfect E2F
consensus sites, should generally be more responsive to E2F
transcription factors than the mouse promoter. Therefore, this
discrepancy alone is unlikely to explain why p107 is up-regulated
and able to compensate for loss of Rb function in the mouse retina
but not the human retina [47] or why mice and patients with an
Rb mutation develop a distinct tumor spectrum. While the E2F
sites are highly conserved across mammalian species, the rest of
the p107 promoter is not, and these other evolutionary changes
may further impact promoter regulation by E2F and other factors.
Interestingly, in humans, single nucleotide polymorphisms (SNP)
of unknown frequency have been identified in the p107 promoter,
including one that deletes one of the 4 Ts in the distal E2F binding
site; while this may not affect E2F binding (only 3 Ts are required
in the consensus sequence), this polymorphism may potentially
alter the physical orientation of the two sites relative to each other
and influence p107 transcription. Future experiments will continue
to dissect the mechanisms regulating p107 transcription, including
the interactions between E2F family members, Rb family
members, and other transcription factors that bind to the p107
promoter. These interactions may also help to explain the tissue-
specificity of expression of p107 in vivo [20,48].
While several binding partners for p107 and its expressionprofile
in various cell types are well known, the unique cellular functions of
p107arestillpoorlyunderstood[2,49].Overexpression ofp107can
arrest some cell types in G1 [50], but loss of p107 function often
results in no visible phenotypes, probably because of functional
compensation by Rb and p130 [13,17].Interestingly, loss of p107 in
neural progenitors results in the activation of Notch signaling and
increased proliferation [51,52]. p107
2/2 mice on a BALB/cJ
background also display a myeloid hyperplasia and mutant MEFs
derived from these mice demonstrate accelerated proliferation [53].
Furthermore, an insertional mutagenesis screen for tumor
suppressor genes identified p107 as a tumor suppressor in B-cell
lymphoma [54]. However, the mechanisms underlying these loss-
of-function phenotypes are still unclear. Some studies have
suggested that p107 may have a particular function during the
progression from late G1 to S phase [55,56], when p107 levels are
highest. We show here that expression of abnormally low levels of
p107 during S phase results in increased cell numbers in a
proliferation assay. Importantly, while the p107 protein is still
expressed and p107 levels found during S phase in p107
E2F-1*2*/1*2*
cells are similar to those found in wild-type cells in G0/G1, and
while BrdU incorporation failed to detect a significant difference
between knock-in mutant cells and wild-type cells, the consequenc-
es for the cell cycle are as strong as in p107 null cells. This
observation indicates that p107 levels are probably critical during
very specific stages of the cell cycle, including during the DNA
replication phase, and this role for p107 during S phase should be
the focus of future studies to elucidate the cellular functions of this
cell cycle regulator.
Unexpectedly, in immortalized MEFs in which p19
ARF has been
knocked-down, the importance of p107 expression during S-phase
is even more evident, as the kinetics of cell cycle re-entry are
altered in the p107
E2F-1*2*/1*2* cells compared to wild-type cells,
whereas these kinetics are unchanged in primary MEFs. This
difference between the function of p107 during S phase in
immortal and primary MEFs is potentially related to an additional
function of p19
ARF during S phase [57]. This function could stem
from a network of interactions between p107, p19
ARF, E2F1 and
c-Myc during S phase [58–63] and these findings could reveal
cooperation between appropriate expression of p107 and p19
ARF in
the control of S phase.
In the absence of Rb, de-repression and/or activation of p107
transcription is thought to result in higher levels of p107 that may
then suppress the functions of activating E2F family members
[64,65]. It is interesting to note that a similar mechanism has
evolved independently in plants [66] and that this type of negative
feedback loop also exists in the control of the cell cycle in yeast
[67], strongly suggesting that this genetic circuitry is a universal
component of the regulatory networks ensuring proper cell cycle
progression. Here, we investigated the mechanisms by which this
feedback loop is activated in mammalian cells using a mouse
genetics approach.
While it has long been hypothesized that direct regulation of the
p107 promoter by Rb is the mechanism by which compensatory
upregulation of p107 occurs in the absence of Rb, our mutant cells
enabled us to distinguish effects of Rb loss on transcriptional and
post-transcriptional compensatory expression of p107. Recently it
has been shown that the p107 protein may be more stable in non-
cycling human hepatocellular carcinoma cell lines when Rb is
absent than when Rb is present [68]. Similarly, we found that in
quiescent MEFs, the p107 protein becomes more stable when Rb is
knocked-down, suggesting that transcriptional regulation alone
may not fully explain compensatory levels of the p107 protein.
Clearly, this increase in p107 protein levels in cycling cells or Rb
mutant cells independent of p107 transcription could serve as a
feedback mechanism to limit the effects of decreased Rb levels.
The relative contribution of transcriptional and post-transcrip-
tional mechanisms of p107 up-regulation in different contexts will
be the focus of future studies.
We hypothesized that disrupting the transcriptional feedback
loop between Rb/E2F and p107 would prevent compensation in
the absence of Rb, such that the low p107 levels observed in
p107
E2F-1*2*/1*2* MEFs would cooperate with decreased Rb
expression, potentially recapitulating some of the phenotypes
observed in Rb;p107 double knock-out MEFs. Additional cell cycle
assays comparing primary and immortalized knock-in mutant
MEFs, both with and without Rb knock-down, failed to reveal
conditions in which the knock-in mutation would cooperate with
loss of Rb in allowing cells to grow in conditions that were
permissive to growth of Rb;p107 double knock-out MEFs (data not
shown). These results suggest that, in most contexts, the lower
stimulation with 20% serum. MCM6 expression is shown as a positive control for cell cycle re-entry, and Tubulin levels are shown as a loading control.
Note that the second, slowly migrating form of p107 at later time points probably reflects p107 phosphorylation during S phase.
doi:10.1371/journal.pgen.1001003.g005
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PLoS Genetics | www.plosgenetics.org 11 June 2010 | Volume 6 | Issue 6 | e1001003Figure 6. Altered p107 expression affects cellular proliferation. (A,B) Immortalized wild-type and p107
E2F-1*2*/1*2* MEFs were synchronized in
G0 through at least three days of serum starvation. DMEM supplemented with 20% BGS was used to stimulate cell-cycle entry. Extracts were collected
at the number of hours indicated post-serum stimulation. (A) RT-qPCR analysis of Cdc6 mRNA in wild-type and p107
E2F-1*2*/1*2* MEFs. (n=3) (B)
Percentage of cells in S-phase, as determined by BrdU/PI staining, at the indicated time points. (n$4) (C) Cell-cycle profiles of asynchronous primary
wild-type, p107
E2F-1*2*/1*2*, and p107
2/2 MEFs. Percentages of cells in each phase were determined by BrdU/PI staining. (n$2) (D) Cellular proliferation
of primary wild-type, p107
E2F-1*2*/1*2*, and p107
2/2 MEFs. Equal numbers of cells were plated at day 0. Cells were then counted every other day from
day 1 to day 9 post-plating. For statistical analysis, p107
E2F-1*2*/1*2* cells were compared to wild-type cells at each time point. (n$13) (E) Model for the
context-dependent regulation of p107 transcription by E2F family members. In cycling mESCs, activating members of the E2F family such as E2F3
bind to the p107 promoter mostly through the distal consensus E2F binding site (site 1). In quiescent MEFs, binding of the E2F4 repressor is also
largely dependent on the presence of the distal consensus site. However, E2F4 may also be recruited to the p107 promoter through interactions with
other transcription factors and/or by binding to other DNA sequences. The size of the E2F boxes indicates the relative binding activity.
doi:10.1371/journal.pgen.1001003.g006
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to overcome the higher levels of p107 observed at other stages of
the cell cycle, at least in terms of reducing the ability of p107 to
compensate in the absence of Rb.
Instead, we found that the increased levels of p107 observed in
quiescentMEFswere able torepress expression of some genes inthe
absence of Rb even better than the increased levels of p107 found in
wild-type MEFs in the absence of Rb. Interestingly, the ability of
increased levels of p107 to compensate for absence of Rb in
repressing E2F target genes during quiescence depends on the
particular gene. Increased levels of p107 protein produced by
transcriptional de-repression and increased protein stability resulted
inrepressed levels ofB-Myb,CyclinA,an dCyclinE buthad nofurther
effect on Cdc6 (Figure 4E and data not shown). These results are
consistent with several studies suggesting that the Rb family
members regulate both distinct and overlapping target genes
[23,69,70]. These observations also suggest that further increasing
p107 levels in Rb mutant cells through a variety of mechanisms may
enhance the compensatory abilities of this Rb family member.
A remaining question is why humans develop retinoblastoma
upon loss of Rb while mice do not. It has recently been
demonstrated that mouse retinal progenitors deficient for Rb
display increased levels of p107 mRNA whereas human retinal
progenitors do not increase the amount of p107 expressed when Rb
is knocked down in culture [47]. This observation, and the fact
that Rb/p107 double mutant mice develop retinoblastoma [71]
supports the idea that p107 levels are important for its tumor
suppressor activity in Rb-deficient retinal cells. However, no system
has been devised to test whether the increased expression of p107
observed in Rb mutant cells directly contributes to the ability of
p107 to compensate for the loss of Rb, or if this increased
transcription is merely coincidental to a constitutive overlapping
function shared by Rb and p107. In other words, it is possible that
basal levels of p107 in Rb mutant cells would be sufficient to
suppress retinoblastoma development. A similar question can be
asked in other cell types in which p107 loss of function by knock-
out enhances tumor development in Rb mutant cells and during
development [13,15,72]. Our results indicate the converse, i.e. that
even higher levels of p107 may more completely compensate in
the absence of Rb, in terms of target gene expression. The
generation of mESCs and MEFs in which the E2F binding sites in
the p107 promoter were singly mutated were intended to discretely
separate the ability of p107 to be activated in the absence of Rb
from other sources of transcriptional regulation. However, these
genetic studies clearly demonstrated that in MEFs, a single E2F
site is critical for both the repression of p107 in non-cycling cells
and the activation of p107 in cycling cells, making the separation of
these two activities impossible. In future experiments, mice
carrying point mutations in the E2F binding sites in the p107
promoter or mice carrying fragments of the human p107 promoter
may help explore the necessity of p107 up-regulation in the
prevention of retinoblastoma in mice by distinguishing between
overlapping and compensatory expression patterns of p107.
Materials and Methods
Ethics statement
Mice were maintained according to practices prescribed by the
NIH at Stanford’s Research Animal Facility accredited by the
AAALAC.
Generation of knock-in p107 BAC and targeting vectors
Recombineering in bacteria [73] was used to generate the
p107
E2F-1*, p107
E2F-2*, and p107
E2F-1*2* BACs. Briefly, BAC clone
RP23-163J20 ordered from BACPAC (http://bacpac.chori.org/)
was transformed into the EL250 strain and the heat-inducible
recombinase present in this strain enabled the insertion of a
Neomycin resistance cassette into intron 1 of p107 by homologous
recombination. Approximately 500 bp of the wild-type promoter
sequence was cloned into pBluescript. Mutation of the E2F sites
was performed using blunt end primers carrying the wild-type
sequence or the point mutations. The 500 bp fragments were then
targeted to the p107 BAC with the conditional Neomycin
resistance cassette. To generate the targeting vectors, we excised
approximately 4 kb upstream of the E2F binding sites and 4 kb
downstream of the Neomycin resistance cassette from the BAC
DNA into a targeting vector backbone carrying a DTA cassette.
Cell culture
mESCs and MEFs were cultured as described previously [74].
For expression analysis in asynchronous MEFs, 3610
5 cells were
plated per 6 cm culture dish. For BrdU/PI analysis in asynchro-
nous MEFs, 2.5610
5 cells were plated per 6 well. Extracts were
collected 48 hours later. For quiescent cell analysis were plated at
higher density: 8610
5 per 6 cm dish, 3610
5 per 6 well, or 1.5610
5
per 12 well. The following day cells were washed twice with PBS
and then cultured in DMEM supplemented with 0.1% serum for
at least 72 hours. For extracts from synchronized MEFs, cells were
rendered quiescent and cultures were re-stimulated with DMEM
supplemented with 20% serum as above after at least 72 hours in
low serum conditions. Extracts were collected at various time
points after stimulation. For proliferation assays, MEFs were
plated at either 2.5610
4 or 5610
4 cells per 12 well on day 0. Cells
were counted in duplicate and were given fresh media every other
day.
For cycloheximide experiments, wild-type MEFs were rendered
quiescent for 3 days as above. At time 0, cycloheximide
(Calbiochem, 25 mg/ml in methanol) or methanol was added to
cells at a concentration of 30 mg of cycloheximide per ml of
DMEM with 0.1% serum.
Luciferase assays
To construct the plasmid reporters, primers were designed to
amplify the p107 promoter from the targeted BAC clones (wild-
type and mutants) to enable cloning directly into the multiple
cloning site of PGL3-basic (Promega). The reverse primer was
positioned to include all sequence upstream of the translation start
site. 1.4610
4 mESCs (V6.5) and 1.25610
4 MEFs were plated in
wells of 48-well plates and transfected one day later. For mESCs,
luciferase activity was read two days after transfection following
the manufacturer’s instructions (Promega). For quiescent MEFs,
luciferase activity was read 24 hours after the withdrawal of serum.
In all luciferase assays, 500 ng of each p107 construct was co-
transfected with 125 ng of a Renilla luciferase vector. For
exogenous E2F3 experiments, 100 ng of DP1 (a gift from the
Dyson lab) was co-transfected with either 100 ng of pCDNA
empty vector or 100 ng of CMV-E2F3. Transfections were carried
out using the Fugene6 Reagent (Roche).
Lentiviral and retroviral infections
Rb knock-down was achieved using the pSicoR lentivirus [75],
as described [18]. The sequence in the Rb cDNA that is targeted
by the shRNA molecules is 59-TGAGAGCAAGGATGTCTCA-
39. p19
ARF and p130 knock-down was achieved using the pSiripp
retrovirus [18], as above. The sequence in the mouse p19 cDNA
that is targeted by the shRNA molecules is: 59-CACCG-
GAATCCTGGACCAG-39. The sequences in the mouse p130
cDNA that is targeted by the shRNA molecules are: 59-
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ATGACCGAG-39.
Generation of mESCs and MEFs with mutations in the
p107 promoter
DTA- p107
E2F-1* and DTA- p107
E2F-1*2* targeting vectors
were electroporated into V26.2 mESCs (C57BL/6) and DTA-
p107
E2F-2* was electroporated into J1 mESCs (129Sv/J). Genomic
DNA from targeted clones was screened by 59 and 39 Southern
analysis, details of which are available upon request. The E2F
binding sites of clones targeted with the neomycin resistance
cassette were sequenced using the primers described for p107
promoter ChIP below. Clones that were appropriately targeted by
the neomycin resistance cassette but that retained wild-type
binding sites were used as wild-type controls. Heterozygous
mESCs for each construct were infected with Ad-Cre and plated
for single colonies. Colonies were picked and screened for
neomycin sensitivity. E2F binding sites were again sequenced to
rule out loss a larger loss of the chromosome. Clones retaining
heterozygous sequence for the binding site(s), as well as the loxP
site in intron 1 were re-targeted and rescreened by Southern
analysis and sequencing.
p107
E2F-1*/1* and p107
E2F-1*2*/1*2* homozygous mutant mESCs
and controls (described above) were injected into wild-type
blastocysts by the Stanford Transgenic Research Facility. MEFs
were derived 11 days post-implantation. Pure populations were
obtained through selection with 600 mg/ml of Geneticin (Invitro-
gen). MEFs were generated from one p107
E2F-1*/1* clone, two
independently targeted p107
E2F-1*2*/1*2* clones, as well as two
independent control clones. Where indicated, immortalized MEFs
were generated through retroviral infection with a vector that
expresses shRNA molecules against p19
ARF [18].
RNA and protein analysis
RNA was extracted from frozen cell pellets with TRIzol
(Invitrogen). TaqMan or SYBR green quantitative PCR was
performed as described previously [20,76]. Rb, p107, TBP, and
CDC6 primers were described previously [76,77]. Other primer
sequences are as follows: for B-Myb, forward primer, 59-TTA AAT
GGA CCC ACG AGG AG-39 and reverse primer, 59-TTC CAG
TCT TGC TGT CCA AA-39; for E2F1, forward primer, 59-TGC
CAA GAA GTC CAA GAA TCA-39 and reverse primer, 59-CTT
CAA GCC GCT TAC CAA TC-39. All relative expression
analyses were calculated relative to TBP (TATA binding protein).
Immunoblots were detected as described previously [74].
Quantitative immunoblot analysis was performed using an
Odyssey Infrared Imager from LI-COR Biosciences. Antibodies
used were as follows: rabbit anti-p107 (sc-318, Santa Cruz
Biotechnology), mouse anti-Rb [78], mouse anti-p130 (BD
610621), goat anti-MCM6 (sc-9843), and mouse anti-PCNA (sc-
56). Loading was verified with antibodies against mouse anti-
alpha-Tubulin (Sigma T9026), by anti-b-Actin (Sigma A5441), or
by staining of total protein with Ponceau.
Chromatin immunoprecipitation
Quantitative chromatin immunoprecipitation (ChIP) for E2F3,
E2F4, p107, and p130 was performed as described previously
[76]. Rb ChIP was performed as described in the Farnham
laboratory protocol (http://genomics.ucdavis.edu/farnham/pdf/
FarnhamLabChIP%20Protocol.pdf) with a few modifications.
Chromatin was sonicated using a Virsonic probe sonicator at
setting 2 at 20% output power for 8 cycles of 15 seconds. The
chromatin was pre-cleared before being diluted and bound by
4 mg of the primary antibody overnight at 4uC. Each ChIP was
then incubated with 8 mg rabbit anti-mouse IgG (MP Biomedicals
#55436) as a secondary for 1 hour. The nucleoprotein complexes
were pulled down by Pansorbin cells (Calbiochem, Cat# 507862).
The DNA was digested with Proteinase K and RNaseA and then
purified by a Qiagen QIAquick PCR Purification Kit. Additional
details are available upon request.
Antibodies used for immunoprecipitations were as follows: E2F3
(sc-878X), E2F4 (sc-1082X), p107 (sc-318X), p130 (sc-317X), p16
(sc-467), Rb [78], and normal mouse IgG (sc-2025).
p107, B-Myb, and Mcm3 promoter binding were assessed
through quantitative PCR using SybrGreenER Mastermix
(Invitrogen). p107 forward, 59-GGT CCA TCT TCT TAT
CCC ATT CCG-39; p107 reverse, 59-CTT CGG GGT TTT
CTT TTC CCT C-39; B-Myb forward, 59-CTC GTG TCT TGT
ACG CTT CGC C-39; B-Myb reverse, 59-CAC GTT CCC AGG
AAC TGC AGC T-39; Mcm3 forward, 59- AGC CAA TCA TAA
CGC GTC TC-39; Mcm3 reverse, 59-CAG CTC CAC ATC ATC
CAG CA-39; actin forward: 59-GCT TCT TTG CAG CTC CTT
CGT TG-39; actin reverse, 59-TTT GCA CAT GCC GGA GCC
GTT GT-39.
Cell cycle assays
For primary and immortal MEF synchronized cell cycle
analysis, cells were pulsed with BrdU for 2 hours prior to
trypsinization. For primary MEF asynchronous cell cycle analysis,
cells were pulsed with BrdU for 4 hours. BrdU and propidium
iodide staining and analysis was performed as described previously
[79], and analyzed on a BD FACSCalibur instrument. Data was
analyzed using FlowJo software (Tree Star).
Subconfluent, immortalized MEFs were trypsinized and
resuspended in DMEM +10% serum at 10610
6 cells/ml.
Hoechst33342 was added at 30 mg/ml and incubated at 37uC
for 1 hour in the dark. Cells were spun and resuspended in 1 ml of
DMEM with fresh Hoechst, strained through a 40 mm cell
strainer and then sorted at the Stanford Shared FACS Facility.
Statistical analysis
Statistical significance was assayed by unpaired Student’s t-test,
except where otherwise indicated. *: p-value,0.05; **: p-value,0.005;
***: p-value,0.0005; ns: not significant. Mean and standard error are
shown.
Acknowledgments
The authors thank Drs. David McPherson and Jan Skotheim for comments
on an earlier version of this article, Drs. Erick Morris and Nick Dyson for
useful reagents, and the members of the Sage lab for helpful discussion
throughout this work, in particular Jamie F. Conklin for additional
technical support.
Author Contributions
Conceived and designed the experiments: DLB JS. Performed the
experiments: DLB SEW AFZ MSK. Analyzed the data: DLB SEW AFZ
MSK JS. Wrote the paper: DLB JS.
References
1. Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the
retinoblastoma gene. Nat Rev Cancer 8: 671–682.
2. Classon M, Dyson N (2001) p107 and p130: versatile proteins with interesting
pockets. Exp Cell Res 264: 135–147.
Mutation of E2F Binding Sites in the p107 Promoter
PLoS Genetics | www.plosgenetics.org 14 June 2010 | Volume 6 | Issue 6 | e10010033. Trimarchi JM, Lees JA (2002) Sibling rivalry in the E2F family. Nat Rev Mol
Cell Biol 3: 11–20.
4. Ewen ME, Xing YG, Lawrence JB, Livingston DM (1991) Molecular cloning,
chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma
gene product-related protein. Cell 66: 1155–1164.
5. Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, et al. (2009)
Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer
Inst 101: 581–591.
6. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, et al.
(2005) Risk of new cancers after radiotherapy in long-term survivors of
retinoblastoma: an extended follow-up. J Clin Oncol 23: 2272–2279.
7. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, et al. (1992) Effects of
an Rb mutation in the mouse. Nature 359: 295–300.
8. Harrison DJ, Hooper ML, Armstrong JF, Clarke AR (1995) Effects of
heterozygosity for the Rb-1t19neo allele in the mouse. Oncogene 10:
1615–1620.
9. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, et al. (1994)
Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary
gland with a nearly complete penetrance. Oncogene 9: 1021–1027.
10. Chen D, Livne-Bar I, Vanderluit JL, Slack RS, Agochiya M, et al. (2004) Cell-
specific effects of RB or RB/p107 loss on retinal development implicate an
intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5:
539–551.
11. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, et al. (2004) Cell type-
specific effects of Rb deletion in the murine retina. Genes Dev 18: 1681–1694.
12. Zhang J, Gray J, Wu L, Leone G, Rowan S, et al. (2004) Rb regulates
proliferation and rod photoreceptor development in the mouse retina. Nat
Genet 36: 351–360.
13. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H (2004)
Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107
and p130. Genes Dev 18: 2952–2962.
14. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC,
et al. (1998) p107 is a suppressor of retinoblastoma development in pRb-deficient
mice. Genes Dev 12: 1599–1609.
15. Berman SD, West JC, Danielian PS, Caron AM, Stone JR, et al. (2009)
Mutation of p107 exacerbates the consequences of Rb loss in embryonic tissues
and causes cardiac and blood vessel defects. Proc Natl Acad Sci U S A 106:
14932–14936.
16. Schneider JW, Gu W, Zhu L, Mahdavi V, Nadal-Ginard B (1994) Reversal of
terminal differentiation mediated by p107 in Rb2/2 muscle cells. Science 264:
1467–1471.
17. Wikenheiser-Brokamp KA (2006) Retinoblastoma family proteins: insights
gained through genetic manipulation of mice. Cell Mol Life Sci 63: 767–780.
18. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T (2003) Acute
mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.
Nature 424: 223–228.
19. Simpson DS, Mason-Richie NA, Gettler CA, Wikenheiser-Brokamp KA (2009)
Retinoblastoma Family Proteins Have Distinct Functions in Pulmonary
Epithelial Cells In vivo Critical for Suppressing Cell Growth and Tumorigenesis.
Cancer Res.
20. Burkhart DL, Viatour P, Ho VM, Sage J (2008) GFP reporter mice for the
retinoblastoma-related cell cycle regulator p107. Cell Cycle 7: 2544–2552.
21. Garriga J, Limon A, Mayol X, Rane SG, Albrecht JH, et al. (1998) Differential
regulation of the retinoblastoma family of proteins during cell proliferation and
differentiation. Biochem J 333 (Pt3): 645–654.
22. Smith EJ, Leone G, Nevins JR (1998) Distinct mechanisms control the
accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell
Growth Differ 9: 297–303.
23. Hurford RK, Jr., Cobrinik D, Lee MH, Dyson N (1997) pRB and p107/p130
are required for the regulated expression of different sets of E2F responsive
genes. Genes Dev 11: 1447–1463.
24. Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, et al. (2004) Unique and
overlapping functions of pRb and p107 in the control of proliferation and
differentiation in epidermis. Development 131: 2737–2748.
25. Mayhew CN, Bosco EE, Fox SR, Okaya T, Tarapore P, et al. (2005) Liver-
specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer
Res 65: 4568–4577.
26. Callaghan DA, Dong L, Callaghan SM, Hou YX, Dagnino L, et al. (1999)
Neural precursor cells differentiating in the absence of Rb exhibit delayed
terminal mitosis and deregulated E2F 1 and 3 activity. Dev Biol 207: 257–270.
27. Zhu L, Xie E, Chang LS (1995) Differential roles of two tandem E2F sites in
repression of the human p107 promoter by retinoblastoma and p107 proteins.
Mol Cell Biol 15: 3552–3562.
28. Aslanian A, Iaquinta PJ, Verona R, Lees JA (2004) Repression of the Arf tumor
suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18:
1413–1422.
29. Takahashi Y, Rayman JB, Dynlacht BD (2000) Analysis of promoter binding by
the E2F and pRB families in vivo: distinct E2F proteins mediate activation and
repression [In Process Citation]. Genes Dev 14: 804–816.
30. Kim SJ, Onwuta US, Lee YI, Li R, Botchan MR, et al. (1992) The
retinoblastoma gene product regulates Sp1-mediated transcription. Mol Cell
Biol 12: 2455–2463.
31. Kim SJ, Wagner S, Liu F, O’Reilly MA, Robbins PD, et al. (1992)
Retinoblastoma gene product activates expression of the human TGF-beta 2
gene through transcription factor ATF-2. Nature 358: 331–334.
32. Morris EJ, Dyson NJ (2001) Retinoblastoma protein partners. Adv Cancer Res
82: 1–54.
33. Shan B, Chang CY, Jones D, Lee WH (1994) The transcription factor E2F-1
mediates the autoregulation of RB gene expression. Mol Cell Biol 14: 299–309.
34. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core
transcriptional regulatory circuitry in human embryonic stem cells. Cell 122:
947–956.
35. Stead E, White J, Faast R, Conn S, Goldstone S, et al. (2002) Pluripotent cell
division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities.
Oncogene 21: 8320–8333.
36. Conklin JF, Sage J (2009) Keeping an eye on retinoblastoma control of human
embryonic stem cells. J Cell Biochem 108: 1023–1030.
37. Wirt SE, Sage J (2010) p107 in the public eye: an Rb understudy and more. Cell
Div 5: 9.
38. Balciunaite E, Spektor A, Lents NH, Cam H, Te Riele H, et al. (2005) Pocket
protein complexes are recruited to distinct targets in quiescent and proliferating
cells. Mol Cell Biol 25: 8166–8178.
39. Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, et al. (2009) RB/
p107/130 pocket proteins: Protein dynamics and interactions with target gene
promoters. J Biol Chem.
40. Vandromme M, Chailleux C, Escaffit F, Trouche D (2008) Binding of the
retinoblastoma protein is not the determinant for stable repression of some E2F-
regulated promoters in muscle cells. Mol Cancer Res 6: 418–425.
41. DeGregori J (2002) The genetics of the E2F family of transcription factors:
shared functions and unique roles. Biochim Biophys Acta 1602: 131–150.
42. Tavner F, Frampton J, Watson RJ (2007) Targeting an E2F site in the mouse
genome prevents promoter silencing in quiescent and post-mitotic cells.
Oncogene 26: 2727–2735.
43. Hong EJ, McCord AE, Greenberg ME (2008) A biological function for the
neuronal activity-dependent component of Bdnf transcription in the develop-
ment of cortical inhibition. Neuron 60: 610–624.
44. Egelkrout EM, Mariconti L, Settlage SB, Cella R, Robertson D, et al. (2002)
Two E2F elements regulate the proliferating cell nuclear antigen promoter
differently during leaf development. Plant Cell 14: 3225–3236.
45. Hateboer G, Wobst A, Petersen BO, Le Cam L, Vigo E, et al. (1998) Cell cycle-
regulated expression of mammalian CDC6 is dependent on E2F. Mol Cell Biol
18: 6679–6697.
46. Johnson DG, Ohtani K, Nevins JR (1994) Autoregulatory control of E2F1
expression in response to positive and negative regulators of cell cycle
progression. Genes Dev 8: 1514–1525.
47. Donovan SL, Schweers B, Martins R, Johnson D, Dyer MA (2006)
Compensation by tumor suppressor genes during retinal development in mice
and humans. BMC Biol 4: 14.
48. Jiang Z, Zacksenhaus E, Gallie BL, Phillips RA (1997) The retinoblastoma gene
family is differentially expressed during embryogenesis. Oncogene 14:
1789–1797.
49. Cobrinik D (2005) Pocket proteins and cell cycle control. Oncogene 24:
2796–2809.
50. Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, et al. (1993) Inhibition
of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev
7: 1111–1125.
51. Vanderluit JL, Ferguson KL, Nikoletopoulou V, Parker M, Ruzhynsky V, et al.
(2004) p107 regulates neural precursor cells in the mammalian brain. J Cell Biol
166: 853–863.
52. Vanderluit JL, Wylie CA, McClellan KA, Ghanem N, Fortin A, et al. (2007)
The Retinoblastoma family member p107 regulates the rate of progenitor
commitment to a neuronal fate. J Cell Biol 178: 129–139.
53. LeCouter JE, Kablar B, Hardy WR, Ying C, Megeney LA, et al. (1998) Strain-
dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in
mice lacking the Rb-related p107 gene. Mol Cell Biol 18: 7455–7465.
54. Suzuki T, Minehata K, Akagi K, Jenkins NA, Copeland NG (2006) Tumor
suppressor gene identification using retroviral insertional mutagenesis in Blm-
deficient mice. Embo J 25: 3422–3431.
55. Kondo T, Higashi H, Nishizawa H, Ishikawa S, Ashizawa S, et al. (2001)
Involvement of pRB-related p107 protein in the inhibition of S phase
progression in response to genotoxic stress. J Biol Chem 276: 17559–17567.
56. Rodier G, Makris C, Coulombe P, Scime A, Nakayama K, et al. (2005) p107
inhibits G1 to S phase progression by down-regulating expression of the F-box
protein Skp2. J Cell Biol 168: 55–66.
57. Yarbrough WG, Bessho M, Zanation A, Bisi JE, Xiong Y (2002) Human tumor
suppressor ARF impedes S-phase progression independent of p53. Cancer Res
62: 1171–1177.
58. Rizos H, Scurr LL, Irvine M, Alling NJ, Kefford RF (2007) p14ARF regulates
E2F-1 ubiquitination and degradation via a p53-dependent mechanism. Cell
Cycle 6: 1741–1747.
59. Datta A, Sen J, Hagen J, Korgaonkar CK, Caffrey M, et al. (2005) ARF directly
binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF.
Mol Cell Biol 25: 8024–8036.
60. Datta A, Nag A, Pan W, Hay N, Gartel AL, et al. (2004) Myc-ARF (alternate
reading frame) interaction inhibits the functions of Myc. J Biol Chem 279:
36698–36707.
Mutation of E2F Binding Sites in the p107 Promoter
PLoS Genetics | www.plosgenetics.org 15 June 2010 | Volume 6 | Issue 6 | e100100361. Datta A, Nag A, Raychaudhuri P (2002) Differential regulation of E2F1, DP1,
and the E2F1/DP1 complex by ARF. Mol Cell Biol 22: 8398–8408.
62. Beijersbergen RL, Hijmans EM, Zhu L, Bernards R (1994) Interaction of c-Myc
with the pRb-related protein p107 results in inhibition of c-Myc-mediated
transactivation. Embo J 13: 4080–4086.
63. Hiebert SW, Lipp M, Nevins JR (1989) E1A-dependent trans-activation of the
human MYC promoter is mediated by the E2F factor. Proc Natl Acad Sci U S A
86: 3594–3598.
64. Calbo J, Parreno M, Sotillo E, Yong T, Mazo A, et al. (2002) G1 cyclin/cyclin-
dependent kinase-coordinated phosphorylation of endogenous pocket proteins
differentially regulates their interactions with E2F4 and E2F1 and gene
expression. J Biol Chem 277: 50263–50274.
65. Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, et al. (2002) E2F4 loss
suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2: 463–472.
66. Sabelli PA, Larkins BA (2006) Grasses like mammals? Redundancy and
compensatory regulation within the retinoblastoma protein family. Cell Cycle 5:
352–355.
67. de Bruin RA, Kalashnikova TI, Chahwan C, McDonald WH, Wohlschlegel J,
et al. (2006) Constraining G1-specific transcription to late G1 phase: the MBF-
associated corepressor Nrm1 acts via negative feedback. Mol Cell 23: 483–496.
68. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, et al. (2010)
Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the
Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells. Gastroenterol-
ogy.
69. Black EP, Huang E, Dressman H, Rempel R, Laakso N, et al. (2003) Distinct
gene expression phenotypes of cells lacking Rb and Rb family members. Cancer
Res 63: 3716–3723.
70. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, et al. (2010) Dissecting
the unique role of the retinoblastoma tumor suppressor during cellular
senescence. Cancer Cell 17: 376–387.
71. Macpherson D (2008) Insights from mouse models into human retinoblastoma.
Cell Div 3: 9.
72. Lara MF, Santos M, Ruiz S, Segrelles C, Moral M, et al. (2008) p107 acts as a
tumor suppressor in pRb-deficient epidermis. Mol Carcinog 47: 105–113.
73. Copeland NG, Jenkins NA, Court DL (2001) Recombineering: a powerful new
tool for mouse functional genomics. Nat Rev Genet 2: 769–779.
74. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, et al. (2000) Targeted
disruption of the three Rb-related genes leads to loss of G(1) control and
immortalization. Genes Dev 14: 3037–3050.
75. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, et al. (2004) Cre-
lox-regulated conditional RNA interference from transgenes. Proc Natl Acad
Sci U S A 101: 10380–10385.
76. Burkhart DL, Ngai LK, Roake CM, Viatour P, Thangavel C, et al. (2010)
Regulation of Rb Transcription in Vivo by Rb Family Members. Mol Cell Biol.
77. Shapiro GS, Van Peursem C, Ornelles DA, Schaack J, DeGregori J (2006)
Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7
protein. J Virol 80: 5349–5360.
78. Ho VM, Schaffer BE, Karnezis AN, Park KS, Sage J (2009) The retinoblastoma
gene Rb and its family member p130 suppress lung adenocarcinoma induced by
oncogenic K-Ras. Oncogene 28: 1393–1399.
79. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL (2005) Global
analysis of proliferation and cell cycle gene expression in the regulation of
hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599–1611.
Mutation of E2F Binding Sites in the p107 Promoter
PLoS Genetics | www.plosgenetics.org 16 June 2010 | Volume 6 | Issue 6 | e1001003